Clinical Trials Sponsored by Alios Biopharma Inc

Total 385 results

Alios Biopharma Inc.

Completed

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Moldova, Republic of, New Zealand, Thailand, Ukraine
Alios Biopharma Inc.

Completed

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

Respiratory Syncytial Virus Infections

France
Alios Biopharma Inc.

Terminated

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Hepatitis C

Belgium
Alios Biopharma Inc.

Withdrawn

A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

Hepatitis B, Chronic
Alios Biopharma Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Chronic Hepatitis C

New Zealand, Moldova, Republic of, Mauritius, United Kingdom
Alios Biopharma Inc.

Completed

A Study of ALS-008176 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

United States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
Alios Biopharma Inc.

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Influenza in Humans

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

Australia, Singapore, United States, New Zealand, Taiwan
Alios Biopharma Inc.

Completed

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Influenza

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

France, Moldova, Republic of, Georgia
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Alios Biopharma Inc.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Healthy

United Kingdom
Alios Biopharma Inc.

Terminated

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Hepatitis B | Chronic Hepatitis B | Viral Hepatitis B

New Zealand
Alios Biopharma Inc.

Completed

A Study to Assess the PK of AL-794 Formulations in Healthy Subjects

Influenza

United Kingdom
Alios Biopharma Inc.
Alexion

Completed

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Chronic Hepatitis C

France
Alios Biopharma Inc.
Janssen Pharmaceutica

Terminated

First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C

Chronic Hepatitits C

Georgia, Moldova, Republic of, France
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Moldova, Republic of
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Terminated

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Australia, New Zealand
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Moldova, Republic of, Romania, France
Alio, Inc.

Recruiting

Alio WEAR Study: Long-term Wear of the Alio Platform

End Stage Kidney Disease

United States
Alio, Inc.

Completed

The ReModel IHC Study for ESRD Patients

Dialysis Access Malfunction

United States
Agios Pharmaceuticals, Inc.

Recruiting

A Safety Study of Single and Multiple Doses of AG-181 in Healthy Participants

Healthy Volunteers

United States
Agios Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period (ACTIVATE-Kids)

Pediatric Pyruvate Kinase Deficiency | Pediatric Hemolytic Anemia

United States, Spain, Germany, Netherlands, Canada, France, Israel, Switzerland, Italy
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (ENERGIZE-T)

Transfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-Thalassemia

Spain, Taiwan, Thailand, United States, France, Canada, Malaysia, Germany, Netherlands, Bulgaria, United Kingdom, Turkey, Italy, Greece, United Arab Emirates, Brazil, Denmark, Lebanon, Saudi Arabia
Agios Pharmaceuticals, Inc.

Active, not recruiting

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Pyruvate Kinase Deficiency

United States, Spain, Japan, Canada, United Kingdom, Korea, Republic of, Ireland, Thailand, Italy, Turkey, Denmark, Brazil, France, Germany, Netherlands, Switzerland
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

Thalassemia

United States, Canada, United Kingdom
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Agios Pharmaceuticals, Inc.

Terminated

A Safety and Tolerability Study of AG-519 in Healthy Subjects

Anemia

United Kingdom
Agios Pharmaceuticals, Inc.

Completed

A Phase I Study of AG-348 in Healthy Volunteers (AG-348MAD)

Healthy Volunteer

United States
Agios Pharmaceuticals, Inc.

Completed

A Phase I Study of AG-348 in Healthy Volunteers (AG-348 SAD)

Healthy Volunteer

United States
Agios Pharmaceuticals, Inc.

Not yet recruiting

A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy

Sickle Cell Disease | Nephropathy
Elios Vision, Inc.

Recruiting

Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery

Open Angle Glaucoma

Spain
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period (ACTIVATE-KidsT)

Pediatric Pyruvate Kinase Deficiency | Pediatric Hemolytic Anemia

United States, Spain, Denmark, Turkey, Netherlands, Czechia, United Kingdom, Germany, Canada, Switzerland
Agios Pharmaceuticals, Inc.

Completed

Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008

Pyruvate Kinase Deficiency

United States, Italy, Netherlands
Agios Pharmaceuticals, Inc.

Terminated

Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) (PKD)

Anemia | Anemia, Hemolytic | Pyruvate Kinase Deficiency | Pyruvate Kinase Deficiency Anemia

United States, United Kingdom, Italy, Spain, Netherlands
Elios Vision, Inc.

Active, not recruiting

Excimer Laser Trabeculostomy Glaucoma Treatment Study (ELTGTS)

Glaucoma, Primary Open Angle

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Anemia, Hemolytic | Pyruvate Kinase Deficiency

United States, Spain, Switzerland, Turkey, Germany, France, United Kingdom, Japan, Netherlands, Brazil, Canada, Czechia, Denmark, Italy, Korea, Republic of, Thailand
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

Healthy Volunteers

United States
Agios Pharmaceuticals, Inc.

Completed

Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

Lymphoma | Advanced Solid Tumors

United States, Spain
Agios Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Healthy Male Participants

United States
Agios Pharmaceuticals, Inc.

Completed

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Myelodysplastic Syndrome | Hematologic Malignancies | Acute Myeloid Leukemia (AML)

United States, France
Agios Pharmaceuticals, Inc.

Completed

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Hepatic Impairment

United States
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

Healthy Volunteers

United States
Agios Pharmaceuticals, Inc.

Completed

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

Healthy

United States
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Healthy | Japanese | Non-Asian

United States
Agios Pharmaceuticals, Inc.

Completed

Drug-Drug Interaction Study of AG120 in Healthy Subjects

Healthy

United States

3

Subscribe